NYSE American - Delayed Quote USD

Armata Pharmaceuticals, Inc. (ARMP)

3.8000 +0.2900 (+8.26%)

At close: November 9 at 4:00:00 PM EST

3.7100 -0.0900 (-2.37%)

After hours: November 9 at 6:19:44 PM EST

 All 
 News 
 Earnings Calls 
 Press Releases 
 SEC Filings 

Armata Pharmaceuticals Strengthens Intellectual Property Portfolio with Two Recent Patent Issuances in the United States

PR Newswire 1mo ago

ARMP
+5.70%
Armata Pharmaceuticals Receives $3.7 Million in Additional Non-Dilutive Funding from U.S. Department of War to Support Advancement of AP-SA02 Phase 3 Development

PR Newswire 1mo ago

ARMP
+5.70%
Armata Pharmaceuticals to Present Data at ISSSI 2026 Showing Defined Genetic Diversity in AP-SA02 May Enhance Killing of Certain Staphylococcus aureus Clinical Isolates

PR Newswire 1mo ago

ARMP
+5.70%
Armata Pharmaceuticals Receives U.S. FDA Breakthrough Therapy Designation for AP-SA02

PR Newswire 1mo ago

ARMP
+5.70%
Armata Pharmaceuticals to Participate in the H.C. Wainwright 28th Annual Global Investment Conference

PR Newswire 1mo ago

ARMP
+5.70%
Armata Pharmaceuticals Announces New Publication That Advances Understanding of Phage Biology to Support Development of Next-Generation Antibacterials

PR Newswire 2mo ago

ARMP
+5.70%
Armata Pharmaceuticals Achieves Key Progress Across Clinical, Regulatory and Manufacturing Activities Supporting Planned Phase 3 Initiation of AP-SA02

PR Newswire 3mo ago

ARMP
+5.70%
Armata Pharmaceuticals Receives Agreement from FDA on Initial Pediatric Study Plan for AP-SA02 for the Treatment of Complicated Staphylococcus aureus Bacteremia

PR Newswire 3mo ago

ARMP
+5.70%
Armata Pharmaceuticals Receives $2.5 Million of Additional Non-Dilutive Award Funding from the U.S. Department of Defense to Support AP-SA02

PR Newswire 4mo ago

ARMP
+5.70%
Armata Pharmaceuticals Announces First Quarter 2026 Results and Provides Corporate Update

PR Newswire 5mo ago

ARMP
+5.70%
INVA
Armata Pharmaceuticals Secures FDA Fast Track Designation for AP-SA02

PR Newswire 6mo ago

ARMP
+5.70%
Armata Pharmaceuticals Announces Structural Biology Publication in "Communications Biology"

PR Newswire 6mo ago

ARMP
+5.70%

Performance Overview

Return	ARMP	S&P 500 (^GSPC)
YTD	-39.49%	+10.29%
1-Year	-34.26%	+12.20%
3-Year	+59.66%	+73.67%

U.S. markets closed

Armata Pharmaceuticals, Inc. (ARMP)

Trading disclosure

Armata Pharmaceuticals Strengthens Intellectual Property Portfolio with Two Recent Patent Issuances in the United States

Armata Pharmaceuticals Receives $3.7 Million in Additional Non-Dilutive Funding from U.S. Department of War to Support Advancement of AP-SA02 Phase 3 Development

Armata Pharmaceuticals to Present Data at ISSSI 2026 Showing Defined Genetic Diversity in AP-SA02 May Enhance Killing of Certain Staphylococcus aureus Clinical Isolates

Armata Pharmaceuticals Receives U.S. FDA Breakthrough Therapy Designation for AP-SA02

Armata Pharmaceuticals to Participate in the H.C. Wainwright 28th Annual Global Investment Conference

Armata Pharmaceuticals Announces New Publication That Advances Understanding of Phage Biology to Support Development of Next-Generation Antibacterials

Armata Pharmaceuticals Achieves Key Progress Across Clinical, Regulatory and Manufacturing Activities Supporting Planned Phase 3 Initiation of AP-SA02

Armata Pharmaceuticals Receives Agreement from FDA on Initial Pediatric Study Plan for AP-SA02 for the Treatment of Complicated Staphylococcus aureus Bacteremia

Armata Pharmaceuticals Receives $2.5 Million of Additional Non-Dilutive Award Funding from the U.S. Department of Defense to Support AP-SA02

Armata Pharmaceuticals Announces First Quarter 2026 Results and Provides Corporate Update

Armata Pharmaceuticals Secures FDA Fast Track Designation for AP-SA02

Armata Pharmaceuticals Announces Structural Biology Publication in "Communications Biology"

Performance Overview